Lung Cancer
From the Journals
HER2-mutant NSCLC confers high brain metastases risk
Patients with HER2-mutated non–small cell lung cancer were more likely to develop brain metastases on therapy than patients with KRAS mutations....
Conference Coverage
Clinical trial enrollment linked to lower death rate in lung cancer patients
ALEXANDRIA, VA. – Access to promising agents, enhanced supportive care, or both could provide direct patient benefit.
Conference Coverage
Out-of-pocket cost of oral TKIs linked to poor lung cancer survival
ALEXANDRIA, VA. – If confirmed in a nationally representative study, findings could have implications for health policy and oncology practice.
From the Journals
HIV drug may enhance efficacy of chemoradiation in locally advanced lung cancer
Strategy incorporating protease inhibitor nelfinavir yields promising efficacy, acceptable toxicity in locally advanced non–small cell lung cancer...
From the Journals
Molecular profiling a must in advanced NSCLC
Identification of targetable mutations and the advent of immune checkpoint inhibitors have improved outcomes for many patients.
From the Journals
Nivolumab yields long-term survival benefit in advanced NSCLC
In a pooled analysis of four studies, the 4-year overall survival with nivolumab was 14%, compared with historical data demonstrating overall...
From the Journals
Local treatment boosts survival for some with oligometastatic lung cancer
Patients treated with a combination of surgical resection and systemic therapy had better overall survival than patients treated with systemic...
From the Journals
Adding chemo beats standard gefitinib for EGFR-mutated lung cancer
For patients with EGFR-mutated, advanced NSCLC, adding pemetrexed and carboplatin to standard gefitinib markedly extends PFS, but at the cost of...
From the Journals
EHR-derived data on tumor progression may predict survival
Real-world data on NSCLC progression drawn from electronic charts correlated with overall survival.
Opinion
Screening for pancreatic and lung cancers
Dr. Alan P. Lyss explores the complexity of shared decision-making in cancer screening.
News
Rozlytrek approved for ROS1-positive metastatic NSCLC, cancers with NTRK gene fusion defects